Alpha Cognition (ACOG) Q1 2026 earnings summary

Executive summary

• Achieved 40% sequential revenue growth in Q1 2026, with net product revenue reaching $3.5 million and cumulative launch revenue at $10.3 million, marking the fourth full quarter of ZUNVEYL commercialization.

• Strong acceleration in prescriber adoption, nursing home penetration, and payer engagement, with commercial reach extended to 2,502 unique nursing homes and 7,900 healthcare providers called on.

• Expanded commercial team to 60 customer-facing representatives and strengthened board governance, including the appointment of Bethany Sensenig.

• Advanced three real-world clinical studies, including BEACON, CONVERGE, and RESOLVE, with BEACON enrollment nearly complete and top-line data expected in early Q3 2026.

• Strengthened intellectual property with two new patents, extending protection through 2045 and opening a $14 billion TBI market opportunity.

Financial highlights

• Q1 2026 net product revenues reached $3.5 million, up from $2.5 million in Q4 2025 (40% sequential growth), and $2.93 million in Q1 2025.

• Operating expenses for Q1 2026 were $11.6 million, up from $10.7 million in Q4 2025 and $6.3 million in Q1 2025; full-year guidance reiterated at $54–$58 million.

• Reported net loss of $6.5 million ($0.30 per share basic, $0.32 diluted) in Q1 2026, compared to $1.7 million ($0.11 per share) in Q1 2025.

• Cash and cash equivalents stood at $54.2 million as of March 31, 2026, down from $66.0 million at year-end 2025; company remains debt-free.

• Licensing revenue declined to $29,977 in Q1 2026 due to a prior one-time IP transfer.

Outlook and guidance

• On track to achieve operating profitability in 2027, supported by current cash reserves and ongoing commercial scaling.

• Full-year 2026 operating expense guidance remains at $54–$58 million; Q2 spending expected to increase modestly as clinical studies ramp up.

• Management expects continued revenue growth from ZUNVEYL as the sales force expands and commercial strategy matures.

• Payer access expected to accelerate through mid-2026 as prescription volume grows; two strategic product approvals in Asia anticipated in 2026 via partner CMS Pharma.

• No revenue guidance provided for 2026.